Back to trial detailsIntake questionnaire
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Applying to The University of Texas MD Anderson Cancer Center (site 127) · Houston, Texas
Answer a few short questions to share with the research team.
0 of 3 answered